DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ZIM LABORATORIES LIMITED (ZIMLAB) share price today?

ZIM LABORATORIES LIMITED (ZIMLAB) is trading at ₹121 on the NSE, down 1.60% on the day. Source: DocStoX.

What is the PE ratio of ZIM LABORATORIES LIMITED?

ZIM LABORATORIES LIMITED has a price-to-earnings (PE) ratio of 111.0 in the Healthcare sector.

What is the market capitalisation of ZIM LABORATORIES LIMITED?

ZIM LABORATORIES LIMITED has a market capitalisation of approximately ₹648 crore.

ZIM LABORATORIES LIMITED

ZIMLAB·NSE·Healthcare

₹121.00▼ -1.97 (-1.60%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹121.00

₹125.42

52W₹59

₹13483%

Open

₹125.42

High

₹125.42

Low

₹121.00

Prev Close

₹122.97

Volume

44.6K

VWAP

₹125.40

Snapshot

Key fundamentals

Market Cap

₹648 Cr

P/E Ratio

111.01Expensive

P/B Ratio

2.25

EPS

₹1.09

Book Value

₹55.40

ROE

1.59%Weak

ROCE

5.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.43Moderate

Face Value

₹10.00

52W High

₹133.90

52W Low

₹59.31

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹46

▼ 62.3%downside

Trading at ₹121 — 62% above our estimate

BearFair valueBull

₹37₹46₹52

/100

Business quality — Watch the fundamentals

Growth 0Profitability 0Efficiency 0Valuation 39

Plain English

Our view

Revenue under pressure recently
Low debt relative to equity
Weak returns on equity (2%)

Strengths

Low debt relative to equity

Risks

Weak returns on equity (2%)
Revenue has been shrinking
Expensive — trades at 111× earnings
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

2% ROE fading to 13% over ~3 yrs, on ₹55 book

₹48

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹37

Analyst target

No analyst coverage

—

Blended fair value₹46

What the numbers say

Investment thesis

Bull case

Low debt relative to equity

Bear case

Weak returns on equity (2%)
Revenue has been shrinking
Expensive — trades at 111× earnings
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

111.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

1.6%Weak

Above 15% is considered healthy for Indian equities

ROCE

5.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.43Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹648 Cr

P/B

2.25

EPS

₹1.09

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 111.0×

Growth

Shrinking

-2% rev CAGR

Profitability

Modest

1.6% ROE

Financial health

Comfortable

D/E 0.43

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹55.96L Cr

Trades114

VWAP₹125.40

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-2.1%

+4.0%

10Y

+3.4%

Profit

-37.0%

-3.0%

10Y

+1.8%

EPS

-39.9%

-6.2%

10Y

—

Profile

Pros

Company's working capital requirements have reduced from 52.8 days to 41.0 days

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has low interest coverage ratio.
Promoter holding has decreased over last quarter: -2.91%
The company has delivered a poor sales growth of 4.03% over past five years.
Promoter holding is low: 30.4%
Company has a low return on equity of 4.54% over last 3 years.
Earnings include an other income of Rs.11.4 Cr.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

30%

Promoter

Promoters

30.3%+0.04

Public

32.8%-36.93

FII / FPI

0.0%

DII

0.1%

Others

36.8%

Total shareholders

16,762

Quarterly trend

Ownership over time

Q4 FY26

Promoter30.34%

DII0.07%

Public32.77%

Others36.82%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1989, Zim Laboratories Ltd manufactures formulation drugs and pre formulation ingredients in India and markets and sells these within and out side India[1]